VOTRIENT Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Votrient, and when can generic versions of Votrient launch?
Votrient is a drug marketed by Novartis and is included in one NDA.
The generic ingredient in VOTRIENT is pazopanib hydrochloride. There are five drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the pazopanib hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Votrient
A generic version of VOTRIENT was approved as pazopanib hydrochloride by APOTEX on October 19th, 2023.
Summary for VOTRIENT
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 102 |
| Clinical Trials: | 103 |
| Patent Applications: | 704 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for VOTRIENT |
| What excipients (inactive ingredients) are in VOTRIENT? | VOTRIENT excipients list |
| DailyMed Link: | VOTRIENT at DailyMed |
Recent Clinical Trials for VOTRIENT
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| National Cancer Institute, France | Phase 1/Phase 2 |
| Centre Leon Berard | Phase 1/Phase 2 |
| University Medicine Greifswald | Phase 2 |
Pharmacology for VOTRIENT
| Drug Class | Kinase Inhibitor |
| Mechanism of Action | Cytochrome P450 2C8 Inhibitors Cytochrome P450 2D6 Inhibitors Cytochrome P450 3A4 Inhibitors Protein Kinase Inhibitors |
Anatomical Therapeutic Chemical (ATC) Classes for VOTRIENT
US Patents and Regulatory Information for VOTRIENT
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis | VOTRIENT | pazopanib hydrochloride | TABLET;ORAL | 022465-001 | Oct 19, 2009 | AB | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| Novartis | VOTRIENT | pazopanib hydrochloride | TABLET;ORAL | 022465-002 | Oct 19, 2009 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for VOTRIENT
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Novartis | VOTRIENT | pazopanib hydrochloride | TABLET;ORAL | 022465-001 | Oct 19, 2009 | ⤷ Try a Trial | ⤷ Try a Trial |
| Novartis | VOTRIENT | pazopanib hydrochloride | TABLET;ORAL | 022465-002 | Oct 19, 2009 | ⤷ Try a Trial | ⤷ Try a Trial |
| Novartis | VOTRIENT | pazopanib hydrochloride | TABLET;ORAL | 022465-002 | Oct 19, 2009 | ⤷ Try a Trial | ⤷ Try a Trial |
| Novartis | VOTRIENT | pazopanib hydrochloride | TABLET;ORAL | 022465-001 | Oct 19, 2009 | ⤷ Try a Trial | ⤷ Try a Trial |
| Novartis | VOTRIENT | pazopanib hydrochloride | TABLET;ORAL | 022465-002 | Oct 19, 2009 | ⤷ Try a Trial | ⤷ Try a Trial |
| Novartis | VOTRIENT | pazopanib hydrochloride | TABLET;ORAL | 022465-001 | Oct 19, 2009 | ⤷ Try a Trial | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for VOTRIENT
See the table below for patents covering VOTRIENT around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Hungary | S1700003 | ⤷ Try a Trial | |
| Norway | 325987 | ⤷ Try a Trial | |
| European Patent Office | 1343782 | COMPOSES CHIMIQUES (PYRIMIDINEAMINES AS ANGIOGENESIS MODULATORS) | ⤷ Try a Trial |
| Portugal | 2311825 | ⤷ Try a Trial | |
| European Patent Office | 2311825 | Pyrimidineamines en tant que modulateurs de l'angiogénèse (Pyrimidineamines as angiogenesis modulators) | ⤷ Try a Trial |
| Germany | 122010000038 | ⤷ Try a Trial | |
| New Zealand | 526542 | Pyrimidineamines as angiogenesis modulators | ⤷ Try a Trial |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for VOTRIENT
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1343782 | 2010C/030 | Belgium | ⤷ Try a Trial | PRODUCT NAME: PAZOPANIB, OPTIONNELLEMENT SOUS LA FORME DE SON SEL PHARMACEUTIQUEMENT ACCEPTABLE OU DE SON SOLVATE; AUTHORISATION NUMBER AND DATE: EU/1/110/628/01 20100616 |
| 1343782 | CA 2010 00024 | Denmark | ⤷ Try a Trial | PRODUCT NAME: PAZOPANIB, EVENTUELT I FORM AF ET FARMACEUTISK ACCEPTABELT SALT ELLER SOLVAT DERAF, HERUNDER HYDROCLORID |
| 1343782 | SPC025/2010 | Ireland | ⤷ Try a Trial | SPC025/2010: 20110401, EXPIRES: 20250613 |
| 1343782 | 122010000038 | Germany | ⤷ Try a Trial | PRODUCT NAME: PAZOPANIB ODER EIN SALZ ODER SOLVAT DAVON; REGISTRATION NO/DATE: EU/1/10/628/001-004 20100614 |
| 1343782 | 10C0037 | France | ⤷ Try a Trial | PRODUCT NAME: PAZOPANIB; REGISTRATION NO/DATE: EU/1/110/628/001 20100614 |
| 1343782 | 389 | Finland | ⤷ Try a Trial | |
| 1343782 | C300456 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: PAZOPANIB, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF SOLVAAT, IN HET BIJZONDER PAZOPANIB HYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/10/628/001-004 20100614 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
